Please provide your email address to receive an email when new articles are posted on . “The most important finding of the trial is the nepafenac Evolute patients had a significantly higher percentage ...

Completion of Facility Enables Initiation of Phase 3 Clinical Trial of Nepafenac in Patients Undergoing Cataract Surgery AUSTIN, Texas, Sept. 12, 2023 /PRNewswire/ -- Mati Therapeutics Inc. ("Mati") ...

A retrospective administrative claims analysis of treatment options for dry eye disease (DED) evaluated treatment patterns and utilization characteristics of patients receiving cyclosporine, punctal ...

The punctal plug delivery system is a minimally invasive drug delivery system that is being developed with a goal of enabling delivery of a variety of drugs to the eye over time through sustained ...

AUSTIN, Texas, Sept. 12, 2023 /PRNewswire/ -- Mati Therapeutics Inc. ("Mati") announced that it has completed and now occupies a facility dedicated to manufacturing all products formulated in Mati's ...